Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement - Takeaways - MDSpire

Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

  • By

  • Kristine A. Karvonen

  • Jean A. McDougall

  • Elizabeth A. Carosso

  • Tina Burrows

  • Solange H. Mecham

  • Chongzhi Di

  • Sarah D. Hohl

  • Elizabeth Stohr

  • Anne Devine

  • Hannah Linden

  • Ajay K. Gopal

  • Evan Y. Yu

  • Andrew J. Cowan

  • Jason A. Mendoza

  • June 16, 2026

  • 0 min

Share

  • 1

    The GUIDE program aims to enhance access to cancer clinical trials for socioeconomically disadvantaged patients through navigation and financial support.

  • 2

    A pilot randomized controlled trial is evaluating the feasibility and preliminary efficacy of GUIDE among 100 adults eligible for clinical trials.

  • 3

    Participants in the GUIDE arm receive navigation services and financial reimbursements, while the control group receives usual care alone.

  • 4

    The study assesses multiple outcomes, including clinical trial enrollment, retention, patient trust, quality of life, and financial burden.

  • 5

    GUIDE addresses critical gaps in clinical trial representation and aims to reduce disparities in access among underrepresented populations.

Original Source(s)

Improving access to therapeutic clinical trials: a randomized controlled trial of GUIDE navigation and reimbursement

  • by Kristine A. Karvonen, Jean A. McDougall, Elizabeth A. Carosso, Tina Burrows, Solange H. Mecham, Chongzhi Di, Sarah D. Hohl, Elizabeth Stohr, Anne Devine, Hannah Linden, Ajay K. Gopal, Evan Y. Yu, Andrew J. Cowan, Jason A. Mendoza

  • June 16, 2026

Related Content

Clinicopathologic features and integrated outcome analysis of pediatric and young adult salivary secretory carcinoma

Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis

Autologous stem cell transplantation for pediatric solid tumors in a resource-limited setting: a single-center experience of 15 years